Skene腺腺癌:4例系列报道
本文报道了1984至2017年约翰霍普金斯泌尿病理咨询服务的4例Skene腺腺癌,平均诊断年龄74.5岁,肿瘤大小1.0-2.0 cm,治疗为局部切除切缘阴性,平均随访40.7个月,3例形态类似前列腺腺泡腺癌(Gleason 4+4=8),均无复发或转移。
要点
- Skene腺腺癌罕见,形态和免疫表型可类似前列腺腺癌。
- 部分病例可显示肠或浆液性分化,需免疫组化鉴别。
- 局部切除后短期随访均无复发或转移。
核心结论
- Skene腺腺癌形态和免疫组化标记可重现前列腺腺癌的特征,但能否沿用前列腺腺癌分级标准尚不明确。
研究设计与样本
- 回顾性系列研究,纳入1984至2017年约翰霍普金斯泌尿病理咨询服务中4例Skene腺腺癌患者。
- 平均诊断年龄74.5岁(范围61至87岁),肿瘤大小1.0至2.0 cm(平均1.5 cm)。
- 治疗为局部切除切缘阴性,平均随访40.7个月(范围4至132个月)。
主要发现
- 3例形态符合前列腺腺泡腺癌,伴筛状、融合和不良腺体,相当于Gleason评分4+4=8;其中1例有混合导管特征。
- 这3例PSA、P501S、NKX3.1和AMACR阳性;1例见CK20阳性、前列腺标记阴性的杯状细胞。
- 第4例为腺状和乳头状结构,假复层柱状上皮和黏液分泌,CK7、ER和P16阳性,前列腺标记阴性。
- PIN4 cocktail在3例中确认起源于既存的尿道旁腺。
- 所有患者末次随访时均存活,无复发或转移。
临床怎么用
- 病理诊断Skene腺腺癌需结合形态和免疫组化,注意与前列腺腺癌鉴别。
- 因罕见且缺乏共识,治疗决策需个体化,局部切除是可选方式。
局限性
- 病例数少(4例),治疗不一,随访有限。
- 无法验证前列腺腺癌分级标准是否适用于Skene腺腺癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Skene's (periurethral) gland adenocarcinoma is very rare, with only 7 cases reported in the literature. This is the first series of cases on this entity. We describe the histologic, immunohistochemical, and clinical findings of 4 patients with Skene's gland adenocarcinoma retrieved from the Johns Hopkins Urologic Pathology Consult Service from 1984 to 2017. The average age at diagnosis of the 4 women was 74.5 years (range, 61 to 87 y). Tumors were treated by limited resections with negative margins. Tumor size ranged from 1.0 to 2.0 cm (mean, 1.5 cm). Average follow-up time was 40.7 months (range, 4 to 132 mo). Three of our cases were morphologically consistent with prostatic acinar adenocarcinoma with variable cribriform, fused, and poorly formed glands, analogous to Gleason score 4+4=8. Of these, one had mixed ductal features with neoplastic cells showing papillary carcinoma with columnar cytology. These 3 lesions were positive for PSA, P501S, NKX3.1, and AMACR. Focal goblet cells positive for CK20 and negative for prostatic markers were seen in one of these cases, suggesting intestinal differentiation (although negative for CDX2 and SATB2). A fourth case had glandular and papillary formations with pseudostratified columnar epithelium and mucin secretion, showing positivity for CK7, ER, and P16, and negativity for prostatic markers, suggesting serous differentiation (although negative for PAX8 and WT1). PIN4 cocktail confirmed the origin in preexisting paraurethral glands in 3 of the cases. All patients were alive and free of recurrence or metastatic disease at the time of last follow-up. Because of the rarity of Skene's gland adenocarcinomas, there is no consensus regarding their treatment. Our findings demonstrate that Skene's gland adenocarcinomas recapitulate morphologies and immunohistochemical markers seen in prostatic adenocarcinoma. However, it is unknown whether applying the same grading criteria for prostatic adenocarcinomas to Skene's gland adenocarcinoma is valid given the small number of cases with variable treatment and limited follow-up.
引用
- Tregnago AC, Epstein JI. Skene's Glands Adenocarcinoma: A Series of 4 Cases. Am J Surg Pathol. 2018. PMID: 29901570. doi:10.1097/PAS.0000000000001108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。